PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of infectdisobgynJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
 
Infect Dis Obstet Gynecol. 2004 Sep-Dec; 12(3-4): 127–133.
PMCID: PMC1784603

Gynecologists' attitudes regarding human papilloma virus vaccination: a survey of Fellows of the American College of Obstetricians and Gynecologists.

Abstract

BACKGROUND: Human papilloma virus (HPV) is the causative agent of cervical neoplasia and genital warts. A vaccine has recently been developed that may prevent infection with HPV. Vaccination for HPV may become a routine part of office gynecology. We surveyed members of the American College of Obstetricians and Gynecologists (ACOG) to determine their attitudes to HPV vaccination. METHODS: A survey was sent to Fellows of ACOG to evaluate gynecologists' attitudes. Vaccine acceptability was analyzed using 13 scenarios with the following dimensions and respective attributes: age of patient (13, 17 and 22 years); efficacy of vaccine (50% or 80%); ACOG recommendation (yes or no); and disease targeted (cervical cancer, warts or both). Each scenario was rated by means of an 11-point response format (0 to 100). Responses were evaluated using conjoint analysis. RESULTS: Of 1200 surveys that were sent out, 181 were returned and included in our analysis. ACOG recommendation was considered the most important variable in vaccine distribution (importance score = 32.2), followed by efficacy (24.5), age (22.4) and, lastly, disease targeted (20.9). Of these variables, higher efficacy was favored; preference was given to age 17 years, with a strong disinclination to vaccinate at age 13 years; and protection against cervical cancer, or genital warts, or both, was significantly favored over a vaccine against genital warts alone. Demographic characteristics of the gynecologists (i.e., age of physician, gender, practice setting and community size) did not play an important role in the decision to recommend vaccination. CONCLUSION: Professional society recommendation is important for acceptability of a potential HPV vaccine. Gynecologists are willing to include this vaccine in their office practice.

Full Text

The Full Text of this article is available as a PDF (101K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997 May 5;102(5A):3–8. [PubMed]
  • Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold A, Manos MM. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 1991 Jan 23;265(4):472–477. [PubMed]
  • Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, Lorincz A, Dalby DM, Janjusevic V, Keller JL. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ. 2000 Sep 5;163(5):503–508. [PMC free article] [PubMed]
  • Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12–19. [PubMed]
  • Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995 Jun 7;87(11):796–802. [PubMed]
  • Stone Katherine M, Karem Kevin L, Sternberg Maya R, McQuillan Geraldine M, Poon Alysia D, Unger Elizabeth R, Reeves William C. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis. 2002 Nov 15;186(10):1396–1402. [PubMed]
  • Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001 Feb 21;93(4):284–292. [PubMed]
  • Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol. 1996 Dec;7(6):373–382. [PubMed]
  • Koutsky Laura A, Ault Kevin A, Wheeler Cosette M, Brown Darron R, Barr Eliav, Alvarez Frances B, Chiacchierini Lisa M, Jansen Kathrin U. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002 Nov 21;347(21):1645–1651. [PubMed]
  • Mays Rose M, Sturm Lynne A, Zimet Gregory D. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med. 2004 Apr;58(7):1405–1413. [PubMed]
  • Mays Rose M, Zimet Gregory D. Recommending STI vaccination to parents of adolescents: the attitudes of nurse practitioners. Sex Transm Dis. 2004 Jul;31(7):428–432. [PubMed]
  • Freed GL, Bordley WC, Clark SJ, Konrad TR. Universal hepatitis B immunization of infants: reactions of pediatricians and family physicians over time. Pediatrics. 1994 May;93(5):747–751. [PubMed]
  • Silins I, Kallings I, Dillner J. Correlates of the spread of human papillomavirus infection. Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):953–959. [PubMed]
  • Shew ML, Fortenberry JD, Miles P, Amortegui AJ. Interval between menarche and first sexual intercourse, related to risk of human papillomavirus infection. J Pediatr. 1994 Oct;125(4):661–666. [PubMed]
  • Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol. 1997 Oct;50(10):1129–1136. [PubMed]
  • Kellerman SE, Herold J. Physician response to surveys. A review of the literature. Am J Prev Med. 2001 Jan;20(1):61–67. [PubMed]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Hindawi Publishing Corporation